Abstract
ObjectiveLittle is known about disease-modifying treatments (DMTs) for multiple sclerosis (MS) and infection risk in clinical practice. We examined the association between DMTs and infection-related medical encounters.MethodsUsing population-based administrative data...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have